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Abstract
Background: Multidrug-resistant Gram-negative bacterial infections are recognized as one of the major threats to
global health. In this study, we describe for the first time blaNDM-1 gene carrying organisms from Ethiopia consisting
of three Acinetobacter baumannii isolates from patients in Jimma.
Methods: Besides phenotypic antimicrobial susceptibility testing, molecular strain typing and sequencing was
performed to describe the phylogenetic relation of the Ethiopian isolates in detail in relation to published isolates
from all over the globe.
Results and discussion: Three multi-resistant, blaNDM-1-positive Acinetobacter baumannii isolates, most likely a local
clonal diffusion, were isolated. Two of the three isolates described within this study were untreatable with the
locally available antimicrobials and were only susceptible to polymyxin B and amikacin. The genome sequences
confirmed the isolates to be distinct from the outbreak strains reported from Kenya, the only other characterized
blaNDM-1 positive Acinetobacter baumannii strains in East Africa so far. Up to date, no other bacterial species were
found to harbour the gene cassette in Jimma and conjugation to E. coli was not successful under laboratory
conditions. However, natural transmission to other bacteria seems likely, given the evident lack of hygienic
precautions due to limited resource settings.
Conclusions: The detected isolates could solely be the tip of the iceberg regarding the presence of NDM-1
producing organisms in the region, as only a limited number of bacterial isolates were evaluated so far and until
recently, susceptibility testing and isolation of bacteria could hardly be performed in clinical patient care. These
multi-drug resistant organisms pose a serious threat to antimicrobial treatments in Jimma, Ethiopia.
Keywords: NDM-1, New Delhi metallo-beta-lactamase, Acinetobacter baumannii, Carbapenemase, Ethiopia, East-
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Background
Multidrug-resistant Gram-negative bacterial infections
are recognized as one of the major threats to global
health, the leading cause of nosocomial infections both
in industrialized as well as developing countries and
leading to a high economic burden [1–4]. These
organisms have efficient capabilities to accumulate re-
sistant traits and pass the genetic determinants to other
bacteria in order to allow them to become drug-resistant
as well [2, 5]. Apart from the genetic characteristics,
other pharmacological and societal factors including hu-
man behaviour at many levels play a significant role for
the emergence and spread of bacterial pathogens resist-
ant to antimicrobials [6, 7]. In developing countries such
as Ethiopia, where there is a high burden of infectious
diseases combined with a lack of resources, the impact
on society is devastating [3, 8]. The sky-rocketing rates
of antibiotic resistant bacteria in developing countries
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are a big threat to the whole health care system includ-
ing the patients in the respective areas as well as at the
global level [2, 3]. The ever increasing travel of people
around the globe is facilitating and speeding up the
spread of resistant organisms across all borders [9, 10].
Although we have learned a lot about the genetics and
molecular biology of multidrug-resistant bacteria from
investigations in industrialized countries, it is in develop-
ing countries where more studies are needed and are a
critical public health priority in order to help with the
design of containment strategies [2, 3].
One of the most common and feared multidrug-
resistant organisms responsible for hospital-acquired in-
fections are Acinetobacter baumannii producing either
extended-spectrum ß-lactamases (ESBL), carbapenemases
or a combination of different factors [11]. Strains of A.
baumannii resistant to carbapenems (CRAB) are regarded
as sentinels for emerging antimicrobial resistance [12].
The most frequent mechanism of resistance are
carbapenem-hydrolyzing class D ß-lactamases (CHDL)
followed by class B metallo-ß-lactamases (MBL) [13, 14].
So far, there are very few reports on CRAB in Africa, and
those published are mostly from northern or southern
African countries, which leaves the precise molecular
epidemiology of those pathogens on this continent un-
identified [13, 15]. In the current literature on CRAB from
African countries, multiple CHDL (OXA-23, OXA-24/40,
OXA-58, and OXA-97) and some MBL (such as NDM-1)
have been described [13, 15, 16].
Jimma University Specialized Hospital (JUSH) is lo-
cated in southwest Ethiopia and constitutes the only re-
ferral hospital for over 15 million people in the
catchment area [17]. Until 2013, no susceptibility testing
and isolation of bacteria could be performed for clinical
patient care at JUSH. As a result, antibiotic therapy was
performed only empirically, predominantly with combi-
nations of different antimicrobial substances. The over-
use of antimicrobial drugs for treatment and prophylaxis
most likely serves as one of the key drivers of resistance
development and increasing treatment failure rates in
the patients [3, 17]. In a collaboration of the University
of Munich (LMU) and the German Center for Infection
Research from Germany (DZIF) together with JUSH, the
establishment of a bacteriology laboratory including an
infectious diseases consulting service was initiated. Since
late 2013, patient samples can be investigated using
common culture based techniques and phenotypic re-
sistance testing up to the standards for patient care.
This report describes to our knowledge the first ana-
lysis of NDM-1 producing Acinetobacter baumannii
isolates in Ethiopia, which were obtained from patient
samples in JUSH. Besides phenotypic antimicrobial sus-
ceptibility testing, molecular strain typing and sequen-
cing was performed to describe the phylogenetic
relation of the Ethiopian isolates in relation to pub-
lished isolates from all over the globe.
Methods
Study setting, specimen collection and patient
characteristics
Jimma University Specialized Hospital (JUSH) is located in
Jimma city, Oromiya regional state, situated at a distance of
more than 350 km southwest of the Ethiopian capital city
Addis Ababa. At the time of the study, JUSH had a capacity
of 450–500 inpatient beds providing curative and prevent-
ive services for over 15 million people within the catchment
area of approximately 15–16,000 km2. Although the hos-
pital is rated as the local referral center, running water and
hand sanitizer were not easily obtainable at the time of the
study. Within 17 months, between January 2014 and June
2015 a total of 224 pure Gram-negative isolates were
obtained from clinically apparent infections from routine
clinical specimens in Jimma. Out of these, 14 could be
identified as Acinetobacter baumannii. Three of these
isolates were found to be meropenem resistant and NDM-1
positive. The samples originate from three independent in-
patients (A–C) attending the surgical department of JUSH.
Basic demographic and medical data were documented
along with the specimens using standard clinical and la-
boratory record forms.
Bacterial isolation and identification
The specimens were inoculated onto appropriate media ac-
cording to standardized protocols. For isolation, 5%
Columbia sheep blood agar as well as MacConkey II agar
was used. Cultivation was performed in incubators at 37 °C
for 24 and 48 h respectively. Blood agar plates were incu-
bated at 5% CO2. After isolation, identification was per-
formed by Gram-stain and using standardized biochemical
reactions (API, bioMérieux SA, Marcy l’Etoile, France).
Antimicrobial susceptibility testing
Isolates were tested against a common panel of antibi-
otics for their susceptibility pattern by disc diffusion
method as outlined by Kirby-Bauer at JUSH bacteriology
laboratory [18] and then retested for antibiotic suscepti-
bilities at the Max von Pettenkofer-Institute (LMU)
using disc-diffusion testing as well as VITEK 2 compact
automated system (N215 and N248, bioMérieux, France)
according to the manufacturer’s instructions. Minimal
inhibitory concentrations (MICs) were determined by
Etest (bioMérieux SA, Marcy l’Etoile, France) and inter-
preted according to the EUCAST guidelines [19].
Molecular characterization
All strains were shipped to the Department of Bacteriology,
Max von Pettenkofer-Institute (LMU), Munich, Germany
for further investigation of their genetic traits using
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molecular methods. Upon receipt, all isolates were sub-
cultured to ensure viability as well as purity and identified
again to species level by MALDI-TOF mass spectrometry
(MALDI Bioytper, Bruker Daltronic, Bremen, Germany) to
exclude errors occurring during transport, labelling and
reading the biochemical differentiation reactions. Bacterial
DNA was isolated from a single colony using the High
Pure PCR Template Preparation Kit (Roche Diagnostics,
Mannheim, Germany) for genetic typing of resistance
mechanisms and from 10 ml of stationary culture using
the NucleoBond PC 20 (MACHEREY-NAGEL, Düren,
Germany) kit as outlined by the manufacturers.
Genetic typing of resistance mechanisms was first per-
formed as a screening with the Check-MDR CT102
Micro-Array Kit (Hain Lifescience, Nehren, Germany)
following the manufacturer’s instructions, allowing for
the detection of CTX-M ESBL enzyme subgroups, TEM
Mutations, SHV Mutations, AmpC alleles CMY, DHA,
FOX, MOX, ACC, MIR, ACT as well as Carbapene-
mases such as KPC, NDM-1, VIM, IMP, OXA-48-like.
To also test for the carbapenemases common in Acineto-
bacter spp., real time PCR reactions were performed to
detect OXA-23-like, OXA24/40-like, OXA-51-like and
OXA-58-like genes [20]. Whole genome sequencing was
performed by Eurofins Genomics (Ebersberg, Germany).
Multi Locus Sequence Typing (MLST) was performed in
silico using the whole genome sequence data according
to the Oxford-scheme [21] and the Sequence Types (ST)
for each strain. The primers used for in silico MLST are
detailed in the supporting information (see Additional
file 1). The algorithm Neighbour-Joining was used to
construct the phylogenetic tree with CLC Genomics
Workbench 6.5 (CLC bio; Aarhus, Denmark). The A.
baumannii sequences and the plasmid sequences used
for comparison were received from the National Centre
for Biotechnology Information (http://www.ncbi.nlm.-
nih.gov/). The strain information and the accession
numbers are listed in the supporting information (see
Additional file 2).
Nucleotide accession numbers
The draft genomes of the three isolates A, B and C have
been deposited at DDBJ/ENA/GenBank under the acces-
sion numbers LWSM00000000, LWSN00000000 and
LWSO00000000 respectively.
Results and discussion
In general, data on the distribution of antimicrobial re-
sistance genes on the African continent is scarce, espe-
cially regarding carbapenemases. To our knowledge, no
blaNDM-1-carrying bacteria or multidrug-resistant A.
baumannii have been described in Ethiopia so far. In
Kenya, an outbreak with NDM-1 producing A. bauman-
nii was recently described, and strain types of the iso-
lates have been determined [15]. Years before, blaNDM-1
could also be demonstrated in Klebsiella in neighbouring
Kenya [22]. We detected three isolates of A. baumannii
harbouring the blaNDM-1 gene within one hospital in
Ethiopia, the Sequence Types were different than the
isolates published from Kenya. We did not perform anal
swab screening to explicitly search for blaNDM-1 positive
bacteria; only clinically relevant materials were exam-
ined. However, the lack of other blaNDM-1-positive iso-
lates is surprising, given the reports about the ease of
horizontal transfer of NDM-1 containing plasmids [9,
23].
The patients’ characteristics of the three NDM-1-carrying
strains
Table 1 shows the basic demographic and medical data
of the three patients. The hospital stay of patients’A and
C was at similar dates. Patients A and B recovered, the
death of patient C was attributed to generalized infection
with the NDM-1 expressing organism. Patient A suffered
Table 1 Basic demographic and medical data of patients A–C
Patient A B C
Patient type Inpatient Inpatient Inpatient
Department ICU, surgical department surgical
department
ICU
Underlying disease Hypertension None Asthma bronchiale
Clinical diagnosis Hemopneumothorax Inguinal abscess Generalized peritonitis secondary to PUD and
bronchial asthma, laparotomy











Travel history None None None
Outcome Improved Improved Died
Treatment with substance tested susceptible depicted in bold
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from hematopneumothorax and developed pleuritis
growing high densities of pure Acinetobacter baumannii
culture from putrid pleural fluid. She was treated with
high dose trimethoprim/sulfamethoxazole after the anti-
microbial susceptibility test result was available and im-
proved with the therapy. This patient could be treated
and survived the infection, whereas patient B and C did
not offer any treatment option given the available drugs
in JUSH. Patient C developed peritonitis after surgical
intervention and grew predominantly Acinetobacter
baumannii from peritoneal fluid. He died due to over-
whelming systemic infection, whereas the otherwise
young and healthy patient B growing pure Acinetobacter
baumannii culture from an inguinal abscess was able to
fight off the infection. During the course of infection,
the process remained localized and treatment was given
with antimicrobials which were tested resistant in the
isolate.
A summary of the antimicrobial susceptibility test re-
sults of the three blaNDM-1-carrying isolates can be seen
in Table 2. One strain was found to differ regarding the
susceptibility against trimethoprim/sulfamethoxazol
(MIC 0.25 μg/ml vs. 32 μg/ml). Otherwise, the anti-
microbial susceptibility patterns were identical, in all
thre methods, VITEK automated testing, E-test as
well as disc diffusion wherever applicable. Disc diffu-
sion testing was performed on MH agar (Mueller-
Hinton Agar, Becton Dickinson, Heidelberg, Germany)
according to EUCAST v 4.0 criteria [19] and was read
on an automated, camera based system (AdagioTM,
Bio-Rad Laboratories GmbH, Munich, Germany).
Growth of the three isolates was detected without any
inhibition zone for chloramphenicol, ciprofloxacin,
erythromycin, amoxicillin, cefoxitin, ceftazidime, cefe-
pime and gentamicin. One isolate (B) showed an in-
hibition of 1 mm around the meropenem disc, the
others did not. The raw values are detailed in Table 2.
Of the substances with inhibition zones, EUCAST v
4.0 only offers cutoff values for disc diffusion for
meropenem (S ≥ 21; R < 15 mm), ciprofloxacin (S ≥ 21;
R < 21 mm), amikacin (S ≥ 18; R < 15 mm) and tri-
methoprim/sulfamethoxazole (S ≥ 16; R < 13 mm). The
susceptibility determined with VITEK as well as E-test
was confirmed by sufficient inhibition zones against
amikacin (22, 23, 23 mm respectively) and trimetho-
prim/sulfamethoxazole for one isolate (25 mm). Re-
markably, there was an inhibition zone around the
tetracycline disc of 18, 20 and 21 mm respectively,
which corresponds to a MIC determined by E-test of
12 μg/ml (Table 2). Despite the inhibition zone there
cannot be any expected in vivo effectivity as tissue
and serum levels even in high doses at peak concen-
trations should not exceed 5 μg/ml [24].
To assess the transferability of the NDM-1 carrying
genetic element to other Enterobacteriaceae, conjugation
experiments against three different polymyxin B
Table 2 Antimicrobial susceptibility testing results for the Acinetobacter baumannii
Antimicrobial compound MIC breakpoint
(μg/ml)
Isolate A Isolate B Isolate C
μg/ml mm μg/ml mm μg/ml mm
S ≤ R > A. baumannii A. baumannii A. baumannii
Chloramphenicol – – >256 n.a. >256 n.a. >256 n.a.
Fosfomycin – – >256 – >256 – >256 –
Ciprofloxacin 1 1 >32 n.a. >32 n.a. >32 n.a.
Erythromycin – – >256 n.a. >256 n.a. >256 n.a.
Amoxicillin – – >256 n.a. >256 n.a. >256 n.a.
Amoxicillin/Clavulanic Acid – – >256 12 >256 13 >256 14
Cefoxitin – – >256 n.a. >256 n.a. >256 n.a.
Ceftazidime – – >256 n.a. >256 n.a. >256 n.a.
Cefepime – – >256 n.a. >256 n.a. >256 n.a.
Meropenem 2 8 >32 n.a. >32 8 [21/15] >32 n.a.
Aztreonam – – >256 – >256 – >256 –
Amikacin 8 16 3 22 [18/15] 3.5 23 [18/15] 3.5 23 [18/15]
Gentamicin 4 4 32 n.a. 32 n.a. 32 n.a.
Trimethoprim/Sulfamethoxazole 2 4 0,25 25 [16/13] 32 n.a. 32 n.a.
Polymyxin B 2 2 1,5 13 1 17 1 17
Tetracycline – – 12 18 12 20 12 21
strains Breakpoints and testing according to EUCAST v 4.0 [19]. Treatment options printed in bold. Disc diffusion diameters in mm in second column; n.a.: no
inhibition around disc 6 mm); −:not performed; Disc diffusion diameter cutoff values shown in brackets in respective relevant fields, if no cutoff values are shown
EUCAST v 4.0 does not indicate a cutoff value
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resistant E. coli mutant strains were conducted. Poly-
myxin B resistant mutants were chosen to allow for effi-
cient selection of transformant E. coli strains, as the donor
organism was resistant to almost all other substances.
Conjugation was performed by co-cultivation of the two
organisms in high density on solid Columbia 5% blood
media (Becton Dickinson, Heidelberg, Germany) for dif-
ferent time periods, as well as in liquid media. Counter se-
lection was performed with Polymyxin B. To enhance
transformation efficiency, F+ strains were also employed.
However, up to now, the blaNDM-1 gene could not be
transferred to E. coli. This observation is obviously not
sufficient to conclude that transfer might not occur be-
tween Acinetobacter strains or in accordance with the lim-
ited spread within the isolates encountered in Jimma. It
might also be explained by low mobilization rates and
chromosomal location of the gene. On the other hand,
transposases were found in silico adjacent to the NDM-1-
cassette and plasmid mobilization as well as pilus assem-
bly genes showed up in the sequence data of the strain.
Genetic traits and Acinetobacter baumannii phylogeny
Upon sequencing, the three isolates exhibited an identical
pattern regarding their MLST profile. It was identified to
be ST957 (http://pubmlst.org/abaumannii/). Already pub-
lished A. baumannii strains from Kenya had different STs
indicating a different origin [15]. The nearest ancestor we
could identify was strain 6200 isolated in Columbia in
2012 which was also grouped as ST957. While no single
nucleotide polymorphism (SNP) was detected in the
analysed housekeeping genes (concatenated sequence
length: 4.284 bp) of the respective three isolates, the
comparison to strain 6200 revealed 28 SNPs. Although
a difference in trimethoprim/sulfamethoxazole resist-
ance was found (Table 2), it is very possible, that these
three isolates isolated in Jimma hospital from independ-
ent patients could reflect clonal diffusion. The phylo-
genetic tree for the documented genomes including
isolates A, B and C is shown in Fig. 1. All three isolates
also harboured the same 115 kb plasmid (without
NDM-1) found in strain 6200, p6200 (NCBI accession
Fig. 1 MLST-based phylogenetic tree using the Oxford-scheme. The Sequence Types, countries and years of isolation are indicated when known.
Green asterisks indicate the proven presence of an NDM-1-plasmid (Isolate A, Isolate B, Isolate C, 6200, B11911, A1, ZW85-1). The scale-bar represents
the number of SNPs per nucleotide
Fig. 2 Gene-map of the NDM-1 cassette as sequenced in the three isolates from Ethiopia. The sequence was found to be identical to published
sequences of NDM-1 in other organisms isolated from multiple places on different continents. There are clearly identifiable transposase genes as well
as other antibiotic resistance genes in close proximity of NDM-1; PRAI: phosphoribosylanthranilate isomerase; TAT: twin-arginine translocation pathway
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number NZ_CP010398), corroborating the relationship
to this strain.
Unfortunately, we were unable to isolate or sequence
the full length of the larger blaNDM-1 containing gene
segment, most likely due to its vast size and repetitive
sequence motifs. It is thus also possible, that the
blaNDM-1 cassette was chromosomally encoded as has
also been described in other strains and thus less easily
transferred to other strains [25, 26]. The inner blaNDM-1
gene-cassette locus with several surrounding genes
(about 6.6 kb) could be assembled from the sequences of
all three strains and was highly similar to the blaNDM-1-
cassettes of previously published strains. The NDM-1
(813 bp) and the blaMBL-gene (366 bp) showed 100% se-
quence identity with the respective genes on the NDM-
1-plasmids of the published A. baumannii strains as well
as from Acinetobacter lwoffi strain Iz4b (NCBI accession
number NC_025000) and Providencia rettgeri strain
09ACRGNY2001 (NCBI accession number KF295828).
This again demonstrates the global distribution of the
NDM-1 gene with vastly identical sequence. The genetic
environment of blaNDM-1 is shown in Fig. 2.
Conclusions
In this study, we describe blaNDM-1 gene carrying organ-
isms from Ethiopia for the first time. The three Acineto-
bacter baumannii isolates from patients in Jimma were
genetically analysed and were found to be distinct from
the outbreak strains isolated in Kenya, the only character-
ized blaNDM-1 positive Acinetobacter baumannii strains in
East Africa so far. This argues strongly against the regional
spread of blaNDM-1 positive organism but rather suggests
the independent, repetitive import of such strains from
other regions. Clinicians should be aware of the possible
emergence of outbreaks with different multi-resistant Aci-
netobacter baumannii strains. Although, no other bac-
terial species were found to harbour the gene cassette
in Jimma so far, and conjugation was not successful
under laboratory conditions, natural transmission to
other bacteria seems likely given the evident lack of
hygienic precautions due to limited resource settings.
It is further likely, that the detected isolates are solely
the tip of the iceberg regarding the presence of
NDM-1 producing organisms in the region, as only a
limited number of bacterial isolates could be evalu-
ated. The three isolates were genetically very closely
related and might represent clonal diffusion within
the surgical department of the hospital.
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